What the FDA labels say about taking them together
Regorafenib and warfarin
Regorafenib's FDA label of February 9, 2026 names warfarin in its warnings and precautions section; the warfarin label PlainMeds reads does not name regorafenib. The regorafenib label: “Monitor INR levels more frequently in patients receiving warfarin.”
Check it at the source: the regorafenib FDA label on DailyMed (effective February 9, 2026, Bayer HealthCare Pharmaceuticals Inc.); the warfarin FDA label on DailyMed (effective May 29, 2026, Amneal Pharmaceuticals LLC).
What does the regorafenib label say about warfarin?
Regorafenib label, warnings and precautionsMonitor INR levels more frequently in patients receiving warfarin [see Clinical Pharmacology ( 12.3 )].
Source: FDA drug label (Stivarga), Bayer HealthCare Pharmaceuticals Inc., effective February 9, 2026 (SPL set 824f19c9-0546-4a8a-8d8f-c4055c04f7c7), via openFDA; the full label on DailyMed
What does the warfarin label say about regorafenib?
Warfarin's label (effective May 29, 2026) does not name regorafenib in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Warfarin Sodium), Amneal Pharmaceuticals LLC, effective May 29, 2026 (SPL set 558b7a0d-5490-4c1b-802e-3ab3f1efe760), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Regorafenib | Warfarin | |
|---|---|---|
| Labeled for | Colorectal cancer | Blood clots (DVT and PE), Atrial fibrillation |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | n/a | $0.093 per tablet 2 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once